Current treatment of papillary thyroid microcarcinoma

Area of Science:

• Endocrinology
• Oncology
• Surgical Oncology

Background:

• Papillary thyroid microcarcinoma (PTMC) is increasingly diagnosed.
• PTMC generally has an excellent prognosis with low disease-specific mortality (<0.5%).
• Accurate prognostic stratification is essential for optimizing surgical management, particularly for high-risk individuals.

Purpose of the Study:

• To review prognostic factors for PTMC.
• To outline current therapeutic recommendations for PTMC.
• To discuss the role of radioactive iodine (RAI) ablation in managing PTMC.

Main Methods:

• Review of established risk factors for PTMC.
• Analysis of treatment guidelines for PTMC.
• Evaluation of indications for RAI ablation post-thyroidectomy.

Main Results:

• Significant risk factors for PTMC include older age, extrathyroidal invasion, lymph node involvement, and distant metastases.
• Total or near-total thyroidectomy is the primary treatment for most PTMCs.
• Neck dissection is reserved for cases with cervical lymphadenopathy or T4 tumors.
• Postoperative RAI ablation is recommended for patients with gross extrathyroidal invasion or distant metastases, aiding in risk assessment via serum Tg levels.

Conclusions:

• Effective risk stratification is key for PTMC management.
• Surgical approach should be tailored based on identified risk factors.
• RAI ablation plays a role in managing high-risk PTMC patients and facilitates postoperative monitoring.